BR112021017561A2 - Método de tratamento de uma doença - Google Patents

Método de tratamento de uma doença

Info

Publication number
BR112021017561A2
BR112021017561A2 BR112021017561A BR112021017561A BR112021017561A2 BR 112021017561 A2 BR112021017561 A2 BR 112021017561A2 BR 112021017561 A BR112021017561 A BR 112021017561A BR 112021017561 A BR112021017561 A BR 112021017561A BR 112021017561 A2 BR112021017561 A2 BR 112021017561A2
Authority
BR
Brazil
Prior art keywords
disease
treating
individual
levoketoconazole
mate1
Prior art date
Application number
BR112021017561A
Other languages
English (en)
Portuguese (pt)
Inventor
Fredric COHEN
Original Assignee
Strongbridge Dublin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72338256&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112021017561(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Strongbridge Dublin Ltd filed Critical Strongbridge Dublin Ltd
Publication of BR112021017561A2 publication Critical patent/BR112021017561A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BR112021017561A 2019-03-04 2020-03-02 Método de tratamento de uma doença BR112021017561A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962813399P 2019-03-04 2019-03-04
PCT/US2020/020644 WO2020180784A1 (en) 2019-03-04 2020-03-02 Methods of treating disease with levoketoconazole

Publications (1)

Publication Number Publication Date
BR112021017561A2 true BR112021017561A2 (pt) 2021-11-09

Family

ID=72338256

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021017561A BR112021017561A2 (pt) 2019-03-04 2020-03-02 Método de tratamento de uma doença

Country Status (10)

Country Link
US (5) US11020393B2 (https=)
EP (1) EP3934649A4 (https=)
JP (2) JP7574204B2 (https=)
KR (2) KR102950333B1 (https=)
CN (1) CN113710250A (https=)
AU (2) AU2020232246B2 (https=)
BR (1) BR112021017561A2 (https=)
CA (1) CA3132319A1 (https=)
IL (1) IL286099A (https=)
WO (1) WO2020180784A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7574204B2 (ja) * 2019-03-04 2024-10-28 ストロングブリッジ ダブリン リミテッド レボケトコナゾールによる疾患の処置方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006204334B2 (en) * 2005-01-10 2012-02-23 Cortendo Ab (Publ) Methods and compositions for treating diabetes, metabolic syndrome and other conditions
AU2007303219A1 (en) * 2006-10-02 2008-04-10 Cortendo Ab (Publ) Ketoconazole enantiomer in humans
TWI690521B (zh) * 2014-04-07 2020-04-11 美商同步製藥公司 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
WO2016048984A1 (en) * 2014-09-25 2016-03-31 Cortendo Ab (Publ) Methods and compositions for the treatment of cushing's syndrome using 2s, 4r ketoconazole
US11261157B2 (en) * 2016-12-08 2022-03-01 Novatarg, Inc. Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy
US10512667B2 (en) * 2017-06-27 2019-12-24 The Regents Of The University Of Michigan Compositions and methods for treating conditions related to adrenocortical activity and/or excessive steroid production
JP7574204B2 (ja) * 2019-03-04 2024-10-28 ストロングブリッジ ダブリン リミテッド レボケトコナゾールによる疾患の処置方法

Also Published As

Publication number Publication date
AU2025204382A1 (en) 2025-07-03
JP7574204B2 (ja) 2024-10-28
AU2020232246B2 (en) 2025-03-20
KR20260049881A (ko) 2026-04-14
US20200397781A1 (en) 2020-12-24
KR20210135278A (ko) 2021-11-12
US20240148724A1 (en) 2024-05-09
US11278547B2 (en) 2022-03-22
JP7801408B2 (ja) 2026-01-16
WO2020180784A1 (en) 2020-09-10
KR102950333B1 (ko) 2026-04-08
IL286099A (en) 2021-10-31
US11020393B2 (en) 2021-06-01
JP2025026838A (ja) 2025-02-26
EP3934649A1 (en) 2022-01-12
US20210267970A1 (en) 2021-09-02
EP3934649A4 (en) 2022-11-23
US11903940B2 (en) 2024-02-20
US20220387425A1 (en) 2022-12-08
US20250387389A1 (en) 2025-12-25
CN113710250A (zh) 2021-11-26
JP2022522873A (ja) 2022-04-20
US12377096B2 (en) 2025-08-05
CA3132319A1 (en) 2020-09-10
AU2020232246A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
Ren et al. Research progress of traditional Chinese medicine against COVID-19
CY1123411T1 (el) Μεθοδοι για την θεραπευτικη αντιμετωπιση πνευμονικων μη-φυματικων μυκοβακτηριακων λοιμωξεων
BR112022021758A2 (pt) Proteína e vacina contra infecção pelo sars-cov-2
CO5700796A2 (es) Composiciones que contienen piperacilina y tazobactam utiles para inyecciones
BR0005276A (pt) Compostos para o tratamento de disfução sexual feminina
ES2193578T3 (es) Complejos de calcio para el enriquecimiento de alimentos.
CO6160236A2 (es) Inhibidor de quinasa
BR112019001457A2 (pt) tratamento e prevenção de distúrbios do sono
MX2022011535A (es) Composiciones y métodos para tratar o prevenir enfermedades inflamatorias que incluyen diabetes mellitus tipo i y tipo ii y enfermedades de la tiroides.
PE20242201A1 (es) Tratamiento de neurofibromas cutaneos con mirdametinib
MX2022000430A (es) Administracion de agonista de sting e inhibidores de puntos de control.
BR112019003710A2 (pt) inibidor de pde7, composto, composição farmacêutica, uso de um inibidor de pde7 ou de um composto, e, método para tratar ou prevenir uma doença que é melhorada pela inibição de pde7.
BR112019023981A2 (pt) injeção de octreotida
MX2023000763A (es) Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrofilas.
BR112021017561A2 (pt) Método de tratamento de uma doença
MX2019009554A (es) Producto de huevo hiperinmunizado para el tratamiento de enteritis necrotica en aves de corral.
Potter et al. Erythrodermic psoriasis after discontinuation of ixekizumab
BR112022017637A2 (pt) Métodos de tratamento do câncer de pulmão de células pequenas e/ou câncer de pulmão de células não pequenas
BR112013024909A2 (pt) composto, composição farmacêutica, método para o tratamento, prevenção ou melhoria de um ou mais sintomas de desordem, doença, ou condição mediada por pi3k, e método para modular a atividade enzimática de pi3k
AR057904A1 (es) Medicamentos que comprenden un agente antimuscerinico y un corticoesteroide
MX2020011769A (es) Derivados de sulfonamida novedosos que tienen actividad inhibidora selectiva de nox.
JOP20250015A1 (ar) تركيبة صيدلانية للأجسام المضادة ضد cd20 واستخداماتها
MX2022003628A (es) Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente.
BR0312452A (pt) Composto; processo para a preparação de um composto; composição farmacêutica; uso de um composto; e método para o tratamento e/ou profilaxia de doenças que são moduladas por agonistas de ppar(alfa) e/ou ppar(gama)
Tiseo et al. Managing skin infections in burn patients: principles and pitfalls

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]